ApexOnco Front Page Recent articles 20 August 2025 Otsuka zips into adjuvant use As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader. 20 August 2025 World Lung 2025 – late-breakers in focus Summit and Nuvalent have scored prized plenary spots. 22 August 2023 More doubts swirl around Lumakras With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval. 21 August 2023 Exelixis claims a label-expanding Cabo success at last However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated. 18 August 2023 A subcutaneous answer to PD-1’s patent problem PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst. 17 August 2023 World Lung 2023 preview – Astra’s Tagrisso showdown Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials. 15 August 2023 A short-lived hold for Arcellx & Gilead Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart. 11 August 2023 Astra goes pivotal with CTLA-4 Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently. Load More Recent Quick take Most Popular